A Placebo-controlled Double-blind Single and Repeated Ascending Dose Study to Investigate the Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2016
At a glance
- Drugs CHF 6001 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Chiesi Farmaceutici SpA
- 08 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 18 Oct 2012 New trial record
- 16 Oct 2012 Results reported in a Chiesi media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History